Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial

卡培他滨 医学 奥沙利铂 内科学 氟尿嘧啶 危险系数 放化疗 肿瘤科 化疗 胃肠病学 癌症 结直肠癌 置信区间
作者
Ruinuo Jia,Tanyou Shan,Anping Zheng,Yaowen Zhang,Ping Lu,Guifang Zhang,Wang Feng,Zhiqiao Xu,Guobao Zheng,Dongxia Tang,Weiguo Zhang,Wanying Li,Ruonan Li,Yibo Guo,Lina Liu,Xiaoyong Luo,Yingjuan Zheng,Zhiwei Chang,Qiming Wang,Xinshuai Wang,Xiaozhi Yuan,Guoqiang Kong,Shuoguo Li,Yang Ruina,Dan Zhou,Jing Ren,Weijiao Yin,Jingxia Li,Junqian Zhang,Ziqi Wang,Manxi Sheng,Bingyi Xu,Liuyan Li,Xiaoyi Liu,Zhihao Lu,Lixin Wan,Fuyou Zhou,Shegan Gao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (20): 2436-2445 被引量:4
标识
DOI:10.1200/jco.23.02009
摘要

PURPOSE This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not. The primary end points were 2-year overall survival (OS) rate and incidence of grade ≥3 adverse events (AEs). RESULTS A total of 246 patients were randomly assigned into the capecitabine (n = 80), XELOX (n = 85), and PF (n = 81) arms. In capecitabine, XELOX, and PF arms, the 2-year OS rate was 75%, 66.7%, and 70.9% (capecitabine v PF: hazard ratio [HR], 0.91 [95% CI, 0.61 to 1.35]; nominal P = .637; XELOX v PF: 0.86 [95% CI, 0.58 to 1.27]; P = .444); the median OS was 40.9 (95% CI, 34.4 to 49.9), 41.9 (95% CI, 28.6 to 52.1), and 35.4 (95% CI, 30.4 to 45.4) months. The incidence of grade ≥3 AEs during the entire treatment was 28.8%, 36.5%, and 45.7%, respectively. Comparing the consolidation chemotherapy with the nonconsolidation chemotherapy groups, the median OS was 41.9 (95% CI, 34.6 to 52.8) versus 36.9 (95% CI, 28.5 to 44) months (HR, 0.71 [95% CI, 0.52 to 0.99]; nominal P = .0403). CONCLUSION Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yu发布了新的文献求助10
1秒前
yolo完成签到,获得积分10
1秒前
cy4psych0完成签到,获得积分10
1秒前
1秒前
3秒前
酷波er应助肯瑞恩哭哭采纳,获得10
4秒前
4秒前
6秒前
Jasper应助禾晏采纳,获得10
6秒前
6秒前
没有蛀牙完成签到 ,获得积分10
6秒前
王子娇发布了新的文献求助10
7秒前
8秒前
夏夏完成签到,获得积分10
8秒前
阿冰发布了新的文献求助10
8秒前
科研蜗牛发布了新的文献求助10
9秒前
治治治关注了科研通微信公众号
9秒前
mochi完成签到,获得积分10
11秒前
豆子应助就晚安喽采纳,获得20
11秒前
11秒前
yu完成签到,获得积分10
11秒前
12秒前
13秒前
cym发布了新的文献求助10
13秒前
萝卜仔完成签到 ,获得积分10
13秒前
wanci应助熊金艳采纳,获得10
14秒前
Hello应助禾晏采纳,获得10
15秒前
纪贝贝完成签到,获得积分10
15秒前
卜靖荷完成签到,获得积分10
15秒前
16秒前
16秒前
zhanghw发布了新的文献求助10
17秒前
20秒前
ElbingX发布了新的文献求助40
20秒前
20秒前
20秒前
佳佳应助科研韭菜采纳,获得10
21秒前
顾矜应助王染墨采纳,获得10
21秒前
dong应助lucy采纳,获得10
22秒前
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976177
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11202970
捐赠科研通 3256899
什么是DOI,文献DOI怎么找? 1798535
邀请新用户注册赠送积分活动 877725
科研通“疑难数据库(出版商)”最低求助积分说明 806516